A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840 Phase 2 ACTIVE_NOT_RECRUITING

The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.

Details

Lead sponsor	Innostellar Biotherapeutics Co.,Ltd
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	50
Start date	2024-01-24
Completion	2029-10

Conditions

• Neovascular Age-Related Macular Degeneration

Interventions

• LX102 subretinal injection
• Aflibercept intravitreal injection

Primary outcomes

• Mean change from baseline in Best Corrected Visual Acuity (BCVA) — 36 weeks
  BCVA measured by ETDRS

Countries

China